← Back to headlines
Stifel Initiates Sutro Biopharma Stock with Buy Rating on ADC Platform
Stifel has begun its coverage of Sutro Biopharma stock with a 'buy' rating, citing confidence in the company's Antibody-Drug Conjugate (ADC) platform.
6 Aug, 20:55 — 6 Aug, 20:55
Sources
Showing 1 of 1 sources
Related Stories
Jane Street Suffers $15 Billion Loss in July Due to Market Ructions
38m ago
Selena Gomez Sued for Alleged Fraud in Mental Health Startup
40m ago
Nvidia Discloses $21 Billion Stake in SpaceX and $30 Billion in Intel
1h ago
Consortium Seals $1.9 Billion Investment in Liverpool FC, Amit Bhatia Named Vice-Chairman
1h ago